{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:24:26Z","timestamp":1792268666821,"version":"4.4.0"},"reference-count":183,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Over the past decade, chronic lymphocytic leukaemia (CLL) treatment has shifted from chemoimmunotherapy to targeted oral agents, predominantly Bruton\u2019s tyrosine kinase inhibitors (BTKis) and the BCL-2 inhibitor venetoclax. These therapies have significantly improved outcomes and are now established as first-line treatment options. However, CLL remains incurable, and resistance or intolerance to both drug classes (double-refractory disease) is an emerging challenge. This has driven the development of novel therapeutic strategies, including non-covalent BTKis such as pirtobrutinib and nemtabrutinib, which retain activity in BTK C481-mutated disease. Next-generation BCL-2 inhibitors (sonrotoclax, lisaftoclax) and BTK degraders are promising in early clinical trials. Immunotherapeutic approaches, such as bispecific T-cell engagers, CD20\/CD3 antibodies, and CAR-T cell therapies, provide additional options for high-risk patients. Although PI3K inhibitors remain under investigation, their role is yet to be defined due to safety concerns. Minimal residual disease (MRD)-guided, fixed-duration regimens represent a significant paradigm shift toward personalised treatment and potentially deeper remissions. Ongoing clinical studies are expected to introduce new effective therapies that may further transform the management of CLL in the coming years.<\/jats:p>","DOI":"10.3390\/jcm14228247","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:50:26Z","timestamp":1763718626000},"page":"8247","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"first","affiliation":[{"name":"Department of Haematology, Medical University of L\u00f3d\u017a, 90-364 L\u00f3d\u017a, Poland"},{"name":"Department of General Haematology and Internal Medicine, Copernicus Memorial, 93-513 L\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2772-8870","authenticated-orcid":false,"given":"El\u017cbieta","family":"Iskierka-Ja\u017cd\u017cewska","sequence":"additional","affiliation":[{"name":"Department of Haematology, Medical University of L\u00f3d\u017a, 90-364 L\u00f3d\u017a, Poland"},{"name":"Department of General Haematology and Internal Medicine, Copernicus Memorial, 93-513 L\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2270-2997","authenticated-orcid":false,"given":"Anna","family":"Pu\u0142a","sequence":"additional","affiliation":[{"name":"Department of Haematology, Medical University of L\u00f3d\u017a, 90-364 L\u00f3d\u017a, Poland"},{"name":"Section of Haematology\/Oncology, University of Chicago, Chicago, IL 60637, USA"},{"name":"Department of Hematooncology and Internal Medicine, Copernicus Memorial Hospital, 93-513 L\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6078-5415","authenticated-orcid":false,"given":"Pawel","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Haematology, Medical University of L\u00f3d\u017a, 90-364 L\u00f3d\u017a, Poland"},{"name":"Department of Hematooncology and Internal Medicine, Copernicus Memorial Hospital, 93-513 L\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0116-5002","authenticated-orcid":false,"given":"Bartosz","family":"Pu\u0142a","sequence":"additional","affiliation":[{"name":"Department of Haematology, Medical University of L\u00f3d\u017a, 90-364 L\u00f3d\u017a, Poland"},{"name":"Department of General Haematology and Internal Medicine, Copernicus Memorial, 93-513 L\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_3","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy","volume":"100","author":"Hallek","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Robak, T., Krawczy\u0144ska, A., Cebula-Obrzut, B., Urbaniak, M., Iskierka-Ja\u017cd\u017cewska, E., and Robak, P. (2023). Atypical chronic lymphocytic leukemia-the current status. Cancers, 15.","DOI":"10.20944\/preprints202307.1468.v1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5603\/ahp.106584","article-title":"Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2025","volume":"56","author":"Hus","year":"2025","journal-title":"Acta Haematol. Pol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/10428194.2023.2188103","article-title":"Is this the end for immunochemotherapy in relapsed\/refractory chronic lymphocytic leukemia?","volume":"64","author":"Robak","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41408-024-01001-1","article-title":"Update on the management of relapsed\/refractory chronic lymphocytic leukemia","volume":"14","author":"Bennett","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s11864-022-00974-0","article-title":"New Treatment options for newly-diagnosed and relapsed chronic lymphocytic leukemia","volume":"23","author":"Obracaj","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zygmunciak, P., Robak, T., and Pu\u0142a, B. (2024). Treatment of double-refractory chronic lymphocytic leukemia-an unmet clinical need. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031589"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Robak, T., Witkowska, M., and Smolewski, P. (2022). The Role of Bruton\u2019s Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions. Cancers, 14.","DOI":"10.3390\/cancers14030771"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood.2024028205","article-title":"Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment for CLL\/SLL","volume":"146","author":"Burger","year":"2025","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): Interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood.2023021959","article-title":"Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL","volume":"143","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2016.12.007","article-title":"Front-line treatment of CLL in the era of novel agents","volume":"53","author":"Robak","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: Final ASCEND trial Results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib versus bendamustine and rituximab in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: Median 5-year follow-up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.26826","article-title":"Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study","volume":"98","author":"Xu","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/17460441.2023.2236547","article-title":"The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies","volume":"18","author":"Robak","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1097\/HS9.0000000000000692","article-title":"Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia","volume":"6","author":"Kutsch","year":"2022","journal-title":"Hemasphere"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/10428194.2024.2333985","article-title":"Bruton\u2019s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): Current progress and latest advances","volume":"65","author":"Schaff","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","article-title":"First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma","volume":"14","author":"Woyach","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"TPS7088","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7088","article-title":"Efficacy and safety of nemtabrutinib in relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: Cohort J of the phase 2 BELLWAVE-003 study","volume":"43","author":"Kipps","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1875.2","DOI":"10.1182\/blood-2024-198731","article-title":"Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study","volume":"144","author":"Tadmor","year":"2024","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1182\/blood-2024-205775","article-title":"LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton\u2019s Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5603\/ahp.104338","article-title":"Acalabrutinib in treatment of patients with chronic lymphocytic leukemia including those at high genetic risk","volume":"56","author":"Robak","year":"2025","journal-title":"Acta Haematol. Pol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5603\/ahp.100523","article-title":"Expert opinion on use of acalabrutinib for chronic lymphocytic leukemia treatment","volume":"55","author":"Jamroziak","year":"2024","journal-title":"Acta Haematol. Pol."},{"key":"ref_43","first-page":"53","article-title":"Zanubrutinib: A novel therapeutic option for the treatment of B-cell neoplasms","volume":"54","author":"Majeranowski","year":"2023","journal-title":"Acta Haematol. Pol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2023-174750","article-title":"Acalabrutinib \u00b1 Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN","volume":"142","author":"Sharman","year":"2023","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib Versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: Interim analysis of a randomized phase III trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for chronic lymphocytic leukemia with TP53 alterations","volume":"383","author":"Ahn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_50","first-page":"3","article-title":"Recommendations on cardiac safety during ibrutinib therapy","volume":"54","author":"Szmit","year":"2023","journal-title":"Acta Haematol. Pol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/17474086.2020.1797482","article-title":"Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies","volume":"13","author":"Lama","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Wi\u015bniewski, K., and Pu\u0142a, B. (2024). A review of resistance mechanisms to bruton\u2019s kinase inhibitors in chronic lymphocytic leukemia. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105246"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/hon.3164_163","article-title":"Characterization of mechanisms of resistance in previously treated chronic lymphocytic leukemia (CLL) from a head-to-head trial of acalabrutinib versus ibrutinib","volume":"41","author":"Woyach","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tips.2024.06.006","article-title":"BTK inhibitors: Past, present, and future","volume":"45","author":"Cool","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/COC.0000000000001170","article-title":"Bruton Tyrosine Kinase Degraders: Current Concepts","volume":"48","author":"Sabakhtarishvili","year":"2025","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Salvaris, R.T., Brennan, J., and Lewis, K.L. (2025). BTK is the target that keeps on giving: A review of BTK-degrader drug development, clinical data, and future directions in CLL. Cancers, 17.","DOI":"10.3390\/cancers17030557"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood.2022016934","article-title":"NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts","volume":"141","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1007\/s00277-025-06515-7","article-title":"Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: Advances and challenges","volume":"104","author":"Wang","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary efficacy and safety of the bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 Study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2024-194839","article-title":"Efficacy and safety of the Bruton\u2019s tyrosine kinase (BTK)degrader NX-5948 in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): Updated results from an ongoing phase 1a\/b study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton\u2019s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2022-164772","article-title":"NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton\u2019s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies","volume":"140","author":"Mato","year":"2022","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4422.1","DOI":"10.1182\/blood-2024-194009","article-title":"Aphase 1 study of AC676, a novel BTK chimeric degrader, in patients with B-cell malignancies","volume":"144","author":"Tees","year":"2024","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1182\/blood-2024-200544","article-title":"Preclinical and first-in-human phase I study of Bruton tyrosine kinase degrader HZ-Q1070 in patients with recurrent or refractory B-cell malignancies","volume":"144","author":"Song","year":"2024","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1158\/1538-7445.AM2023-3450","article-title":"Abstract 3450: Discovery and preclinical study of novel BTK degrader HZ-Q1070","volume":"83","author":"Liu","year":"2023","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"TPS7091","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7091","article-title":"A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed\/refractory B-cell malignancies","volume":"42","author":"Chong","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1182\/blood-2022-167308","article-title":"Discovery and Preclinical Study of Novel BTK Degrader HZ-Q1060","volume":"140","author":"Liu","year":"2022","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO study: Final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Robrecht","year":"2024","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2024-199175","article-title":"Sonrotoclax and Zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: Data from an ongoing phase 1\/1b Study BGB-11417-101","volume":"144","author":"Soumerai","year":"2024","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-22-3321","article-title":"Novel BCL-2 Inhibitor lisaftoclax in relapsed or refractory chronic lymphocytic leukemia and other hematologic malignancies: First-in-human open-label trial","volume":"29","author":"Ailawadhi","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/blood-2024-205998","article-title":"Abbv-453: A highly potent and selective next generation small molecule inhibitor of BCL-2","volume":"144","author":"Phillips","year":"2024","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.clml.2025.01.018","article-title":"A First-in-human phase I study of LOXO-338, an oral selective Bcl-2 inhibitor, in patients with advanced hematologic malignancies","volume":"25","author":"Kwiatek","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_77","unstructured":"Liang, Y., Zhu, Z., Liao, A., Yu, W., Peng, H., Zhou, F., Huang, X., Cui, G., Ge, J., and Li, F. (2025, January 12\u201315). MRD guided mesutoclax plus orelabrutinib for CLL\/SLL demonstrates high response and early mrd clearance with good tolerability: Preliminary analysis from an ongoing phase II dose optimization study. Proceedings of the European Hematology Association (EHA) 2025 Congress, Milan, Italy."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7038","DOI":"10.1200\/JCO.2025.43.16_suppl.7038","article-title":"Preliminary safety and efficacy data of ICP-248, a novel BCL2 inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"43","author":"YI","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/17425255.2019.1606211","article-title":"Venetoclax in the treatment of chronic lymphocytic leukemia","volume":"15","author":"Wolowiec","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_80","first-page":"647","article-title":"Venetoclax: A novel treatment for patients with del(17p) chronic lymphocytic leukemia","volume":"8","author":"Borg","year":"2017","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00277-023-05304-4","article-title":"Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group","volume":"102","author":"Morawska","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: Primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1200\/JCO.22.02283","article-title":"Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study","volume":"41","author":"Munir","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00070-6","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"Kater","year":"2024","journal-title":"Lancet. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease. Reply","volume":"390","author":"Munir","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1056\/NEJMoa2409804","article-title":"fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. Reply","volume":"392","author":"Brown","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1182\/blood-2023-174465","article-title":"Zanubrutinib and venetoclax as initial therapy for CLL\/SLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)","volume":"142","author":"Allan","year":"2023","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1021\/acs.jmedchem.4c00027","article-title":"Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2","volume":"67","author":"Guo","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2023019706","article-title":"Sonrotoclax overcomes BCL2 G101V mutation\u2013induced venetoclax resistance in preclinical models of hematologic malignancy","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood-2023-179541","article-title":"Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 Inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma (TN-CLL\/SLL): Data from an ongoing phase 1\/2 study","volume":"142","author":"Tam","year":"2023","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1158\/1078-0432.CCR-21-4037","article-title":"Lisaftoclax (APG-2575) Is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy","volume":"28","author":"Deng","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1182\/blood-2023-183071","article-title":"Updated efficacy and safety results of lisaftoclax (APG-2575) inpatients (Pts) with Heavily pretreated chronic lymphocytic leukemia (CLL): Pooled Analyses of Two Clinical Trials","volume":"142","author":"Zhou","year":"2023","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1182\/blood-2022-160386","article-title":"Lisaftoclax (APG-2575) Safety and activity as monotherapy or combined with acalabrutinib or rituximab in patients (pts) with treatment-na\u00efve, relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (R\/R CLL\/SLL): Initial data from a phase 2 global study","volume":"140","author":"Davids","year":"2022","journal-title":"Blood"},{"key":"ref_100","first-page":"9","article-title":"PI3K inhibitors in chronic lymphocytic leukemia: Where do we go from here?","volume":"108","author":"Brown","year":"2023","journal-title":"Haematologica"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Hus, I., Pu\u0142a, B., and Robak, T. (2022). PI3K Inhibitors for the treatment of chronic lymphocytic leukemia: Current status and future perspectives. Cancers, 14.","DOI":"10.3390\/cancers14061571"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III Study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/ajh.25634","article-title":"Combination trial of duvelisib (IPI-145) with rituximab or bendamustine\/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia","volume":"94","author":"Flinn","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.2020007376","article-title":"Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K\u03b4 inhibitor therapy","volume":"137","author":"Mato","year":"2021","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/bloodadvances.2020001800","article-title":"The dual PI3K\u03b4\/CK1\u03b5 inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells","volume":"4","author":"Maharaj","year":"2020","journal-title":"Blood Adv."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: An open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11523-019-00668-y","article-title":"Absorption, distribution, and binding profile of ME-401, a potent and selective oral small-molecule inhibitor of phosphatidylinositol 3-Kinase \u03b4 (PI3K\u03b4) inanimal and B-cell lymphoma models","volume":"14","author":"Moreno","year":"2019","journal-title":"Target. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.19994","article-title":"A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study","volume":"206","author":"Munakata","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.1200\/JCO.2020.38.15_suppl.8016","article-title":"Tolerability and durable respones of the PI3K\u03b4 inhibitor ME-401 administered on an intermittent schedule in relapsed\/refractory (R\/R) follicular lymphoma (FL) and other B-cell malignancies","volume":"38","author":"Zelenetz","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/bloodadvances.2023010648","article-title":"A phase 2 study of the PI3K\u03b4 inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)","volume":"8","author":"Phillips","year":"2024","journal-title":"Blood Adv."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Ramchandren","year":"2019","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/1538-7445.AM2020-664","article-title":"Abstract 664: BGB-10188, a highly selective PI3K\u03b4 inhibitor with improved safety profile and superior anti-tumor activities in vivo","volume":"80","author":"Yang","year":"2020","journal-title":"Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/blood.V122.21.4418.4418","article-title":"RP6530, a dual PI3K\u03b4\/\u03b3 inhibitor, attenutates AKT phosphorylation and induces apoptosis in primary cutaneous T cell lymphoma (CTCL) cells","volume":"122","author":"Lewis","year":"2013","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.V122.21.678.678","article-title":"First-In-Human Study of AMG 319, a Highly Selective, Small Molecule Inhibitor of PI3K\u03b4, In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies","volume":"122","author":"Lanasa","year":"2013","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/1538-7445.AM2022-5454","article-title":"Abstract 5454: Amdizalisib (HMPL-689), a highly selective PI3K\u03b4 inhibitor, exhibits potent anti-tumor activity in pre-clinical B-cell lymphoma models","volume":"82","author":"Hu","year":"2022","journal-title":"Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00280-022-04493-5","article-title":"Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3K\u03b4 [(14)C] SHC014748M in healthy Chinese subjects following oral administration","volume":"91","author":"Guo","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.neo.2020.10.004","article-title":"SHC014748M, a novel selective inhi-bitor of PI3K\u03b4, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia","volume":"22","author":"Fan","year":"2020","journal-title":"Neoplasia"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41392-024-01798-0","article-title":"Phase II study of novel orally PI3K\u03b1\/\u03b4 inhibitor TQ-B3525 in relapsed and\/or refractory follicular lymphoma","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-021-01140-z","article-title":"Phase 1 clinical trial of the PI3K\u03b4 inhibitor YY-20394 in patients with B-cell hematological malignancies","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: Expert panel opinion","volume":"56","author":"Coutre","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-19-3061","article-title":"Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed\/Refractory CLL or SLL in the DUO Crossover Extension Study","volume":"26","author":"Davids","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-134783","article-title":"Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Na\u00efve (TN) and Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study","volume":"136","author":"Gribben","year":"2020","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"101053","DOI":"10.1016\/j.neo.2024.101053","article-title":"A highly selective PI3K\u03b4 inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon","volume":"57","author":"Yang","year":"2024","journal-title":"Neoplasia"},{"key":"ref_127","first-page":"773","article-title":"A phase Ib study result of HMPL-689, a PI3K\u03b4 inhibitor, in Chinese patients with relapsed\/refractory lymphoma","volume":"32","author":"Cao","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"8058","DOI":"10.1200\/JCO.2020.38.15_suppl.8058","article-title":"Safety and efficacy of TQ-B3525, a novel and selective oral PI3K \u03b1\/\u03b4 inhibitor, in Chinese patients with advanced malignancies: A phase I dose-escalation and expansion trial","volume":"38","author":"Wang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1080\/14712598.2024.2413365","article-title":"The role of antibody therapies in treating relapsed chronic lymphocytic leukemia: A review","volume":"24","author":"Witkowska","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/art.11354","article-title":"B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations","volume":"48","author":"Stohl","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2014-08-593269","article-title":"A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL","volume":"124","author":"Woyach","year":"2014","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1080\/10428194.2021.1964020","article-title":"Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor","volume":"62","author":"Staber","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1200\/JCO.2021.39.15_suppl.7556","article-title":"Phase 1\/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)","volume":"39","author":"Lee","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/blood-2022-167153","article-title":"Phase 1\/2 Study of Zilovertamab and ibrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or marginal zone lymphoma (MZL)","volume":"140","author":"Lee","year":"2022","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nri2297","article-title":"CCR7 and its ligands: Balancing immunity and tolerance","volume":"8","author":"Rot","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Cuesta-Mateos, C., Brown, J.R., Terr\u00f3n, F., and Mu\u00f1oz-Calleja, C. (2021). Oflymph nodes and CLL cells: Deciphering therole of CCR7 in the pathogenesis of CLL and understanding its potential as therapeutic target. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.662866"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1917484","DOI":"10.1080\/19420862.2021.1917484","article-title":"Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: The paradigm of CLL","volume":"13","author":"Loscertales","year":"2021","journal-title":"mAbs"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/hon.3213","article-title":"Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax","volume":"41","author":"Loscertales","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00262-021-03014-2","article-title":"Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody","volume":"71","author":"Loscertales","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood.2021014760","article-title":"ROR1: An orphan becomes apparent","volume":"140","author":"Kipps","year":"2022","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41375-020-01055-7","article-title":"Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1\/2 phosphorylation via a ROR1\/DOCK2-dependent mechanism","volume":"35","author":"Hasan","year":"2021","journal-title":"Leukemia"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Xian, J., Sinha, N., Girgis, C., Oh, C.S., Cring, M.R., Widhopf, G.F., and Kipps, T.J. (2024). Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein. Biomedicines, 12.","DOI":"10.3390\/biomedicines12071573"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"6517","DOI":"10.1182\/blood-2023-191114","article-title":"Combined Therapy of Zanubrutinib and Zilovertamab in the Inhibition of Invasive Capability of Chronic Lymphocytic Leukemia Cells","volume":"142","author":"Hasan","year":"2023","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"EVIDoa2100001","DOI":"10.1056\/EVIDoa2100001","article-title":"Zilovertamab Vedotin targeting of ROR1 as therapy for lymphoid cancers","volume":"1","author":"Wang","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40164-025-00644-5","article-title":"Immunotherapy in chronic lymphocytic leukemia: Advances and challenges","volume":"14","author":"Gao","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5603\/ahp.100752","article-title":"Bispecific antibodies in relapsed\/refractory diffuse large B-cell lymphoma","volume":"55","author":"Danecki","year":"2024","journal-title":"Acta Haematol. Pol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Visentin, A., Frazzetto, S., Trentin, L., and Chiarenza, A. (2024). Innovative combinations, cellular therapies and bispecific antibodies for chronic lymphocytic leukemia: A narrative review. Cancers, 16.","DOI":"10.3390\/cancers16071290"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"6804","DOI":"10.1182\/blood-2024-193052","article-title":"Future landscapes of bispecific antibodies in chronic lymphocytic leukemia (CLL). Systematic review of ongoing trials","volume":"144","author":"Shahzad","year":"2024","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2024-199708","article-title":"Epcoritamab monotherapy in patients (Pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL): Results from CLL expansion and optimization cohorts of Epcore CLL-1","volume":"144","author":"Danilov","year":"2024","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2021-146563","article-title":"Subcutaneous epcoritamab in patients with relapsed\/refractory chronic lymphocytic leukemia: Preliminary results from the Epcore CLL-1 Trial","volume":"138","author":"Kater","year":"2021","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1182\/bloodadvances.2022009517","article-title":"Cytotoxicity of the CD3\u00d7CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting","volume":"7","author":"Mhibik","year":"2023","journal-title":"Blood Adv."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2023-173796","article-title":"Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter\u2019s Transformation","volume":"142","author":"Cheah","year":"2023","journal-title":"Blood"},{"key":"ref_155","first-page":"1269","article-title":"Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma","volume":"109","author":"Song","year":"2024","journal-title":"Haematologica"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hon.3163_28","article-title":"Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter\u2019s transformation","volume":"41","author":"Hutchings","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1182\/blood-2022-159586","article-title":"A Phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma: Recommended dose safety\/efficacy update and escalation exposure-response analysis","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/blood-2023-188444","article-title":"GB261, an Fc-function enabled and CD3 affinity De-Tuned CD20\/CD3 bispecific antibody, demonstrated a highly advantageous safety\/efficacy balance in an ongoing first-in-human dose-escalation study in patients with relapsed\/refractory non-Hodgkin lymphoma","volume":"142","author":"Song","year":"2023","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood-2022-169658","article-title":"First-in-human phase I trial of a ROR1 targeting bispecific t cell engager (NVG-111) in combination with ibrutinib or as monotherapy in subjects with relapsed refractory chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL)","volume":"140","author":"Townsend","year":"2022","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Shin, H.G., Yang, H.R., Yoon, A., and Lee, S. (2022). Bispecific antibody-based immune-cell engagers and their emerging therapeutic targets in cancer immunotherapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105686"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"TPS7091","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7091","article-title":"TITANium: An open-label, global multicenter phase 1\/2 study of AZD5492, a first-in-class subcutaneous CD8-guided tri-specific T-cell engager (TCE), in patients (pts) with relapsed or refractory (r\/r) B-cell malignancies","volume":"43","author":"Shadman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1158\/1538-7445.AM2023-5679","article-title":"Abstract 5679: Tetra-specific antibody GNC-035: Guidance and navigation control (GNC) molecule development for treatment of ROR1+ malignancies","volume":"83","author":"Khalili","year":"2023","journal-title":"Cancer Res."},{"key":"ref_163","first-page":"228","article-title":"Biological activity validation of a computationally designed Rituximab\/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action","volume":"4","author":"Cai","year":"2021","journal-title":"Antib. Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2024-198745","article-title":"Pre-clinical evaluation of AZD5492, a novel CD8-guided T cell engager, for B-non Hodgkin lymphoma indications","volume":"144","author":"Lawrence","year":"2024","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1158\/1538-7445.AM2025-3513","article-title":"Abstract 3513: CC312, a trispecific CD19-targeting co-stimulatory T cell engager, for the treatment of B cell malignancies and autoimmune diseases","volume":"85","author":"Huang","year":"2025","journal-title":"Cancer Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.3390\/curroncol29050293","article-title":"CAR T cell therapy for chronic lymphocytic leukemia: Successes and shortcomings","volume":"29","author":"Todorovic","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_168","first-page":"34","article-title":"Modern immunotherapy using CAR-T cells in haemato-oncology and solid tumors","volume":"55","author":"Bogacz","year":"2024","journal-title":"Acta Haematol. Pol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41571-025-00992-5","article-title":"Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma","volume":"22","author":"Bock","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): A multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2021","journal-title":"Blood"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1016\/S2152-2650(24)01266-7","article-title":"CLL-184 characteristics associated with response to lisocabtagene maraleucel (liso-cel) in patients with R\/R CLL\/SLL: Exploratory analyses from the phase 1\/2 TRANSCEND CLL 004 Study","volume":"24","author":"Wierda","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood.2024027460","article-title":"ZUMA-8: A phase 1 study of brexucabtagene autoleucel in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"146","author":"Davids","year":"2025","journal-title":"Blood"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1182\/blood-2022-167868","article-title":"ZUMA-8: A phase 1 study of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in Patients With Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"140","author":"Davids","year":"2022","journal-title":"Blood"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1182\/bloodadvances.2023011399","article-title":"Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed\/refractory CLL","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/s41375-024-02392-7","article-title":"Third-generation anti-CD19 CAR T cells for relapsed\/refractory chronic lymphocytic leukemia: A phase 1\/2 study","volume":"38","author":"Derigs","year":"2024","journal-title":"Leukemia"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e026644","DOI":"10.1136\/bmjopen-2018-026644","article-title":"Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: A unicentre phase I\/II clinical trial protocol","volume":"9","author":"Schubert","year":"2019","journal-title":"BMJ Open"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41375-025-02574-x","article-title":"Emerging T-cell lymphomas after CAR T-cell therapy","volume":"39","author":"Braun","year":"2025","journal-title":"Leukemia"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/17474086.2025.2545344","article-title":"Indicators of an increased risk of therapy-related myeloid neoplasms in lymphoma patients: How can we best evaluate severe impairment of bone marrow function?","volume":"18","author":"Kubicki","year":"2025","journal-title":"Expert Rev. Hematol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8247\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T10:05:17Z","timestamp":1763719517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":183,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14228247"],"URL":"https:\/\/doi.org\/10.3390\/jcm14228247","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}